A solid-phase enzyme immunoassay method for the measurement of total and class-specific serum antibodies to Campylobacterjejuni was developed. The test was found to be both sensitive and specific. Immunoglobulin M, G, and A antibodies were detected in about 90% of sera collected from patients recovering from Campylobacter enteritis, with the pattern of appearance and decline of these antibodies conforming to that usually seen in an acute infection. A poor antibody response was noted in patients with intermittent or prolonged enteritis. The clinical implications and diagnostic value of this test are discussed.

SUMMARYA bacteriological study was made of blood specimens taken repeatedly during a 2-year period from a child with subacute bacterial endocarditis who received intensive treatment with antibiotics. The conventional bacillary form of Corynebacterium sp. was present in the blood and bone marrow of the patient before the beginning of antibiotic therapy and on occasions when the administration of antibiotics was suspended. These were the periods when the patient showed overt symptoms of clinical illness. When antibiotic therapy was adequate to produce clinical remission of symptoms, the infecting organism was not eradicated, but persisted in the blood in a small granule-like form that could be demonstrated and cultured only by highly specialized techniques. The cultural procedures required to bring about reversion of the granule-like form to the conventional bacillary form and the morphology of the various transitional forms that the organism assumed during the reversion process are described and illustrated.

Background Strongyloidiasis can cause devastating morbidity and death in immunosuppressed patients. Identification of reliable biomarkers for strongyloidiasis in immunosuppressed patients is critical for the prevention of severe disease. Methods In this cross-sectional study of solid organ transplant (SOT) candidates and recipients, we quantified Strongyloides-specific IgG to the recombinant NIE-Strongyloides antigen and/or to a soluble extract of S. stercoralis somatic antigens (“crude antigen”) using enzyme-linked immunosorbent assays (ELISAs). We also measured peripheral eosinophilia, 4 different eosinophil granule proteins, and intestinal fatty acid–binding protein (IFABP). Results We evaluated serum biomarkers in 149 individuals; 77 (52%) pre-SOT and 72 (48%) post-SOT. Four percent (6/149) tested positive by NIE ELISA and 9.6% (11/114) by crude antigen ELISA (overall seropositivity of 9.4% [14/149]). Seropositive patients had higher absolute eosinophil counts (AECs) than seronegative patients (P = .004). AEC was positively correlated to the levels of eosinophil granule proteins eosinophil cationic protein (ECP) and eosinophil peroxidase (EPO) (P < .05), while IFABP was positively related to the 2 other eosinophil granule proteins (major basic protein [MBP] and eosinophil-derived neurotoxin [EDN]; Spearman’s r = 0.3090 and 0.3778, respectively; P < .05; multivariate analyses slopes = 0.70 and 2.83, respectively). Conclusions This study suggests that, in SOT patients, strongyloidiasis triggers both eosinophilia and eosinophil activation, the latter being associated with intestinal inflammation. These data provide insight into the pathogenesis of S. stercoralis infection in the immunocompromised population at high risk of severe strongyloidiasis syndromes.

Gardnerella vaginalis is known to be associated with bacterial vaginosis and has less frequently been reported to contribute to polymicrobial gynecologic and postsurgical infections in women. It is not considered to be a common cause of disease in men. We now report a case of pyelonephritis with G. vaginalis bacteremia in a male patient with nephrolithiasis. We found 10 other cases of Gardnerella infection in men and reviewed the predisposing factors, case descriptions, treatments, and outcomes. Infection due to G. vaginalis in men is rare, but it should be considered to be a potential pathogen men, especially in those with urogenital tract abnormalities.

Background The SARS-CoV-2 pandemic has caused over 400,000 deaths worldwide thus far, and poses therapeutic challenges for millions of patients. There is currently no treatment for SARS-CoV-2 infection approved by the United States Food and Drug Administration. Multiple agents have been used off-label to treat SARS-CoV-2 infection based on small observational cohorts and in vitro data. Here we present the experience of a large academic medical center in treating SARS-CoV-2 infection. Methods We performed a retrospective cohort study of patients admitted for greater than 24 hours with a nasopharyngeal, oropharyngeal, and/or bronchoalveolar lavage sample positive for SARS-CoV-2 by polymerase chain reaction (PCR). Demographic data, comorbidities, clinical data, and treatment data were collected from the electronic medical record. Off-label therapies were used at the discretion of the treating providers guided by regularly updated treatment guidelines assembled by infectious diseases physicians and antimicrobial stewardship pharmacists. The primary outcome assessed was in-hospital mortality. Secondary outcomes included admission to the intensive care unit (ICU), endotracheal intubation, initiation of vasopressors, and drug-related adverse events. Results Data collection was completed for 448 patients admitted between March 18, 2020 and May 8, 2020. All-cause in-hospital mortality was 13.4% (60/448) during this time. Mortality rates increased with age, up to 45% for patients over 80 years old. Male sex, hypertension, chronic pulmonary disease, end-stage renal disease, chronic liver disease were also risk factors for increased mortality. QTc interval prolongation occurred significantly more frequently in patients who received hydroxychloroquine (HCQ) with or without azithromycin(AZM) than those who did not (HCQ 6%, HCQ+AZM 7.8% vs all other patients, 0%, p< .0001). Review of treatment trends showed close adherence to the treatment recommendations at that time (Figure 1). Patient Characteristics Admission Laboratory Data by Disease Severity QTc Prolongation Conclusion SARS-CoV-2 infection is associated with significant inpatient mortality, and use of off-label treatments was associated with significant drug-related adverse events. Treatment regimens changed rapidly, and providers adhered closely to institutional guidelines as they evolved. Treatment Trends by Week QTC pre/post Treatment by Hydroxychloroquine Use vs. No Hydroxychloroquine Use Disclosures Samir Gupta, MD, Gilead Sciences (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member)ViiV (Consultant, Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Research Grant or Support)